Survodutide What it is: Dual GLP-1 and glucagon receptor agonist
Im having trouble locating it but, Id like to send you an email
In the study, the authors report that of the 8,803 patients who took Wegovy in the trial, 569 (6.5%) had a heart attack or another cardiovascular event, compared with 701 of the 8801 patients (8.0%) in the placebo group
Start losing weight today safely & medically supervised Personalized programs for metabolism, energy, and real results
Author contributions AS: Visualization, Formal Analysis, Writing original draft, Investigation, Validation, Data curation
Hannah Cooper After years of struggling with my weight, GLP-1 finally helped me stay consistent without feeling hungry all the time